"Identifying ‘risk genes’ is providing incredible insight into the biological mechanisms involved in tipping the balance from health to disease." John Hardy
UK DRI Group Leader
Prof John Hardy is a world-leading neurogeneticist in the field of neurodegenerative diseases, receiving numerous accolades that include the Breakthrough Prize in Life Sciences, the Brain Prize and, in 2009, being elected a Fellow of the Royal Society. In 1991, Hardy's team uncovered the first mutation directly implicated in Alzheimer's disease leading to the formulation of the highly influential 'amyloid-cascade' hypothesis. His extensive body of work in genetics will be built upon in this UK DRI programme, where the team will unravel pathogenic networks in neurodegenerative disease.
1. At a glance
Using genetics to build a better understanding of dementia
The causes of dementia are usually complex and involve a combination of genetic, environmental and lifestyle factors. Thanks to advances in DNA sequencing technologies, we have now discovered several genetic variations that can influence a person’s chance of developing a disease. Identifying these so-called ‘risk genes’ is providing incredible insight into the biological mechanisms involved in tipping the balance from health to disease.
In fact, with many risk genes for neurodegenerative diseases already uncovered, scientists are beginning to investigate the key relationships between them in order to improve our understanding of disease mechanisms. In addition, these studies help us gain a holistic view of how the genes interact so that we ascertain the chance that an individual will develop one of these conditions.
Prof John Hardy is aiming to build complex disease networks for different neurodegenerative diseases. His work involves using bioinformatic approaches to analyse gene activity and genetic data from cells, human brain tissue and laboratory models. He is working closely with other researchers to test the predicted networks through laboratory experiments in cells and tissues. He hopes this approach will ultimately lead to the development of new treatments that can stop, slow down or reverse dementia.
2. Scientific goals
In the major neurodegenerative diseases, discoveries in genetics, and the following analysis has traditionally been valued solely as a driver for molecular investigation. However, with the massive increase in identified genetic loci driven by GWAS and by whole-exome and whole-genome sequencing, the balance of information transfer is shifting: so many genetic loci have now been discovered for the major neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, Motor Neuron Disease and to a lesser extent frontotemporal dementia (FTD)) that we are now able to distinguish emerging networks of genes involved in pathogenesis. Importantly, these networks now allow us to have a better understanding of genetic risk, not just in terms of individual genes but in genetic variability in processes driving pathogenesis.
It is now possible to use bioinformatics to predict which particular genes and pathways are likely to be involved in neurodegenerative diseases – the expertise of John Hardy’s Lab. The first successful example of this was the identification of the TREM2 network in amyloid response in mice, pointing to the new genetic loci PLCG2 and ABI3. Results from the team have also shown that nearly all the pure FTD genes are lysosomal, nearly all the FTD/ALS genes belong to the ubiquitin-proteasome pathway and that ataxia genes are likely to be involved in calcium homeostasis, the ubiquitin-proteasome system or DNA repair.
This programme will involve the use of whole-genome expression analysis in cells, mouse models and human brains. The bioinformatic analysis that follows will help guide ongoing genetic investigation in these diseases, in order to unravel disease pathways. This bioinformatic information will be shared with collaborators working on cell and animal systems, and those working on disease biomarkers, to drive a programme of work designed to advance our understanding of disease pathogenesis and devise novel therapeutic approaches.
Main objective and research goal:
The overall aim is to build pathogenic networks for neurodegenerative diseases based on network analyses of expression and genetic data and then to begin to test these networks through experimental work in relevant tissues and cells in collaboration with others.
3. Team members
June Smalley (PA)
Dr Kin Mok (Postdoctoral Researcher)
Dr Dervis Salih (Postdoctoral Researcher)
Maryam Shoai (Postdoctoral Researcher)
Daniah Trabzuni (Postdoctoral Researcher)
Hanya Benotmane (Research Technician)
Will Scotton (PhD Student)
Within UK DRI:
- Prof Bart De Strooper, UK DRI at UCL
Beyond UK DRI:
- Dr Selina Wray, UCL
- Prof Rick Livesey, UCL Institute of Child Health/Gurdon Institute
- Dr Jenny Pocock, UCL
- Dr Mina Ryten, UCL
- Prof Frances Edwards, UCL
Gene expression, diseased brain tissues, stem cells, bioinformatics, neurodegeneration
Transcriptomics, single cell analyses, CRISPR, mouse models, iPS cells
7. Key publications
Goate AM, Chartier-Harlin MC, Mullan MC, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor MN, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 349 (1991) 704-706. (Cited 3334)
Hutton M, L endon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA, Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F, Tannenberg T, Dodd PR, Hayward N, Kwok JB, Schofield PR, Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink P. Coding and splice donor site mutations in tau cause autosomal dominant dementia (FTDP-17). Nature (1998) 393:702-5 (Cited 2282)
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 Jul 19;297(5580):353-6. (Cited 7476)
Singleton A., Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003 Oct 31;302(5646):841 (Cited 2253)
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J; Alzheimer Genetic Analysis Group 2013. Trem2 variants in Alzheimer's disease. N Engl J Med 368, no. 2: 117-27. (Cited 915)